: 5'-deoxyadenosylcobalamin (AdoCbl) combines with L-methylmalonyl-CoA mutase EC 5.4.99.2) to catalyze the conversion of L-methylmalonyl-CoA to succinyl-CoA; and methylcobalamin (MeCbl) is required for 5-methyltetrahydrofolate-homocysteine methyltransferase (5-methyltetrahydropteroyl-tri-L-glutamate:L-homocysteine S-methyltransferase; EC 2.1.1.13) activity which catalyzes the methylation of homocysteine to methionine and the formation of tetrahydrofolate from 5-methyltetrahydrofolate.
port of this biochemical heterogeneity, using heterokaryons prepared by Sendai-virus-mediated cell fusion. Nine fibroblast lines from patients with defective Cbl metabolism (4 cbl A, 3 cbl B, and 2 cbl C), two from patients with defective mutase apoenzyme, and two from controls were fused in Pairwise combinations and tested for functional mutase hooenzyme using a radioautographic procedure which detects fusions were later discontinued in favor of the "positive control" described above. A number of fusions were carried out two or more times and these are indicated in Table 2 (Fig. 2b) . Most of the cbl mutants were scored 0 or 1+ while a few mutants, demon- strating a more "leaky" phenotype, tended to be scored 2+ (Fig. 2c) . Some variability was noted in the scoring. It was often difficult to distinguish between 0 and 1+; and cells scored against a high background produced by a thick coating of emulsion were most often read 1+ or 2+. Nevertheless, in no case did a mutant strain ever score higher than 2+, and mutant strains were easily distinguished from controls. These results confirm the findings of Hill and Goodman (6) in tests of similar mutant and control strains.
Individual strains were treated with inactivated Sendai virus to produce multinucleate homokaryons. Such "self-fusions" always gave silver grain patterns similar to those of the unfused parent strain. The cells in Fig. 2d are from the self-fusion of a normal strain. As with the unfused cells in Fig. 2a , these multinucleate cells were completely covered with a dense blanket of silver grains. Most self-fusions of mutant strains gave scores of 0 or 1+, comparable to their unfused counterparts. Fig. 2e and f show the silver grain patterns of representative self-fusions of mutant strains. Nuclei are readily discernible in these photographs because there are very few silver grains over the cells. As with unfused cells, some self-fusions produced scores as high as 2+. Three mutants consistently giving 2+ scores were strains 221 and 245, both cbl A mutants, and strain-215 (Fig. 2f), a We propose that each of these complementation groups identifies a different locus; that, together, they define four independent gene loci; and that the observed complementation is, therefore, intergenic. Two independent lines of evidence support this proposal. First, each set of noncomplementing mutations lies within a single gene according to Benzer' s classic interpretation of the cia-trans test (11) . That is, the absence of complementation in any given heterokaryon indicates that the defect of each parental genome must be at the same locus. Since we observed four sets of noncomplementing heterokaryons, we infer the existence of four genes. A theoretical exception to this rule is the failure of a polarity mutant to complement a point mutation in a distal gene of an operon or gene cluster (12, 13) , but such phenomena are very rare and have been observed only in bacteria and fungi. Second, the prominent biochemical differences both between the mutase apoenzyme and the Cbl mutants (1, 7) , and among the Cbl mutants (4, 5) (1975) 3185 that these two classes reflect mutations at the same locus and that the complementation observed between them is intragenic. For instance, one step in AdoCbh synthesis could be catalyzed by an enzyme composed of two identical subunits and bound to the mitochondrial membrane. In intact cells or homokaryons, different mutations of this enzyme (i.e., cbl A or B) could produce an indistinguishably severe block in AdoCbl synthesis, whereas, when the mitochondrial membrane is altered or destroyed during the preparation of cell extracts, the subunits of the cbl A-type mutant enzyme could assume a configuration restoring near normal enzymatic activity. To complete this formulation, complementation in heterokaryons between cbl A and cbl B mutants could reflect formation of hybrid enzyme with activity far greater than that of either parent line. Clearly, an unambiguous distinction between intragenic and intergenic complementation of these mutants must await their biochemical characterization.
The occasional demonstration of affected sibs and the approximately equal numbers of affected males and females has suggested that each of the methylmalonicacidemias is inherited in vivo as an autosomal recessive trait. This assump- tion has not yet been tested by statistical analyses in pedigrees or by heterozygote detection. The results of our complementation tests confirm that the three defects of Cbl metabolism and the defect of the mutase apoenzyme are expressed as recessive mutations in heterokaryons, since each can be complemented by fusion with cells of a class other than their own. It is unlikely that the expression of a dominant allele could have been masked by an excess of normal alleles, because complementation was observed regularly in dikaryons as well as heterokaryons containing several nuclei.
Some patients with methylmalonicacidemia respond to administration of pharmacologic doses of vitamin B12 with decreased accumulation of methylmalonic acid and clinical improvement (7, 14) . Such responsive patients appear to be restricted to those with defects of Cbl metabolism. Among the nine patients with Cbl defects whose fibroblast lines were examined in this study, seven have been tried on vitamin B12 therapy. Three of the cbl A and one of the cbl B patients are responsive to vitamin B12 (ref. 14, and unpublished observations) while one patient from each group (cbl A, K.B.; cbl B, T.S.) showed no improvement after short-term therapeutic trials (15) . If these results are confirmed with long-term therapeutic trials, it would imply that mutations of the same Cbl gene can lead to different clinical expression of the defect. This would underscore still additional heterogeneity and preclude the use of complementation analysis to determine the likelihood that vitamin B12 therapy would be effective.
Beginning with the demonstration of complementation between mutations of independent loci on the X chromosome in human diploid cells (16) , several metabolic defects have been successfully subjected to complementation tests. Genetic heterogeneity has been demonstrated in cells from patients with galactosemia (17), xeroderma pigmentosum (18) (19) (20) , maple syrup urine disease (21) , and hexosaminidase deficiency (22, 23) . It is apparent that genetic complementation is proving to be an effective tool for the elucidation of the genetic basis of inherited metabolic disease.
